

10/569472


AP12 Rec'd PGT/PTO 22 FEB 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I, VIVIEN IRENE COULSON, declare:

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland, residing at 96 Langley Road, Watford, Hertfordshire, WD17 4PJ;
2. That I am well acquainted with the French and English languages;
3. That the attached is a true translation into the English language of the certified copy of European Patent Application No. 03292145.4 filed 1 September 2003;
4. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardise the validity of the patent application in the United States of America or any patent issuing thereon.

Declared this 29th day of November 2005



V.I. COULSON



---

**European  
Patent Office**

## **Certificate**

The attached documents are exact  
copies of the European patent  
application described on the following  
page, as originally filed.

---

**Patent application No.**

**03292145.4**

**For the President of the  
European Patent Office**

**[signature]**

**C. v.d. Aa-Jansen**



European  
Patent Office

Application no.: 03292145.4

Date of filing: 01.09.03

**Applicant(s):**

Les Laboratoires Servier  
12, Place de La Défense  
92415 Courbevoie Cedex  
FRANCE

**Title of the invention:**  
(If no title is shown please refer to the description.)

New process for the synthesis of N-[(S)-1-carboxybutyl]-(S)-alanine esters and application in the synthesis of perindopril

**Priority(ies) claimed**  
State/Date/File no.:

**International Patent Classification:**


C07C227/00

**Contracting states designated at date of filing:**

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO  
SE SI SK TR LI

The present invention relates to a process for the synthesis of N-[(S)-1-carboxybutyl]-(S)-alanine esters, and to their application in the synthesis of perindopril and its pharmaceutically acceptable salts.


More specifically, the present invention relates to a new process for the synthesis of the compounds of formula (I) :



wherein R represents a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group,

and addition salts thereof with a mineral or organic acid or base.

The compounds of formula (I) obtained according to the process of the invention are useful in the synthesis of perindopril of formula (II) :



and in the synthesis of its pharmaceutically acceptable salts.

Perindopril and its pharmaceutically acceptable salts have valuable pharmacological properties.

Their principal property is that of inhibiting angiotensin I converting enzyme (or kininase II), which allows, on the one hand, prevention of the conversion of the

decapeptide angiotensin I to the octapeptide angiotensin II (a vasoconstrictor) and, on the other hand, prevention of the degradation of bradykinin (a vasodilator) to an inactive peptide.

Those two actions contribute to the beneficial effects of perindopril in cardiovascular diseases, more especially arterial hypertension and heart failure.

Perindopril, its preparation and its use in therapeutics have been described in the European patent specification EP 0 049 658.


In view of the pharmaceutical value of that compound, it has been important to be able to obtain the intermediate of formula (I) by an effective synthesis process that allows in particular, the selective production of the (S,S) diastereoisomer in a good yield and with an excellent degree of purity, but that is equally readily transposable to an industrial scale.

Some methods for the preparation of the compounds of formula (I) are already known.

- The journal Tet. Lett. 1982, 23 (16), 1677-80 describes the production of a compound of formula (I) (R = ethyl) by the reaction in ethanol of ethyl 2-oxovalerate with alanine tert-butyl ester in the presence of sodium cyanoborohydride.
- The patent specification EP 0 309 324 describes the production of a compound of formula (I) (R = ethyl) by the reaction in dimethylformamide of alanine benzyl ester with ethyl  $\alpha$ -bromovalerate in the presence of triethylamine.
- The patent specifications EP 0 308 340 and EP 0 308 341 describe the production of a compound of formula (I) (R = ethyl) by the reaction in water of ethyl norvalinate hydrochloride with pyruvic acid in the presence of hydrogen, palladium-on-carbon and sodium hydroxide.


The Applicant has now developed a new process for the industrial synthesis of compounds of formula (I).

More specifically, the present invention relates to a process for the synthesis of compounds of formula (I) which is characterised in that a morpholinone of formula (III) :



5        wherein P represents a protecting group for the amino function,  
is reacted

- either with allyl bromide or allyl triflate, in the presence of a base, to yield a compound of formula (IV) having the (3S,5S) configuration :




wherein P is as defined hereinbefore,

10        which is hydrogenated in the presence of palladium-on-carbon,

- or with iodopropane,


to yield a compound of formula (V) having the (3S,5S) configuration :



15        wherein P is as defined hereinbefore,

which is subjected to the action of LiOH, then to the action of an esterification reagent,

to yield a compound of formula (VI) :



wherein R and P are as defined hereinbefore,

which is reacted with an oxidising agent to yield, after deprotection of the amino function, the compound of formula (I).

Among the protecting groups for the amino function that can be used in the present invention there may be mentioned, without implying any limitation, the groups tert-butoxycarbonyl and benzyloxycarbonyl. The preferred P group is the tert-butoxycarbonyl group.

Among the bases that can be used for the reaction between the compound of formula (III) and allyl bromide or allyl triflate there may be mentioned, without implying any limitation, lithium diisopropylamide (LDA), sodium bis(trimethylsilyl)amide (NaHMDS) and potassium tert-butanolate.

Among the esterification reagents that can be used for the formation of the compound of formula (VI) there may be mentioned, as preferred, the compounds of formula (VII) :



wherein R is as defined for formula (I), and X represents a triflate, tosylate or mesylate group or a halogen atom, preferably iodine.

When it is desired to obtain compounds of formula (I) wherein R represents a methyl group, the esterification reagent may also be diazomethane.

Among the oxidising agents that can be used for the oxidation of the compound of formula (VI) there may be mentioned, without implying any limitation,  $\text{NaIO}_4$  in the presence of  $\text{RuCl}_3$ .

The oxidation may also be carried out in two steps, by first converting the compound of formula (VI) to the corresponding aldehyde, for example under Swern conditions, then oxidising the aldehyde to the corresponding carboxylic acid, for example using  $\text{KMnO}_4$ .

The compounds of formula (V) and (VI) are new products, useful as synthesis intermediates in the chemical or pharmaceutical industry, especially in the synthesis of perindopril, and as such form an integral part of the present invention.

The group R that is preferred is the ethyl group.

The compound of formula (III) can be obtained starting from (S)-N-benzylalaninol, which is reacted with ethyl bromoacetate in the presence of triethylamine to yield, after cleaving the benzyl group, (S)-N-(ethoxycarbonylmethyl)alaninol, which is then protected by the group P as defined hereinbefore, which is then cyclised by reaction with paratoluenesulphonic acid.

**Example : N-[(S)-Ethoxycarbonyl-1-butyl]-(S)-alanine hydrochloride**

**Step A :tert-Butyl (3S,5S)-3-allyl-5-methyl-2-oxo-4-morpholinecarboxylate :**

Introduce into a reactor 200 g of tert-butyl (5S)-5-methyl-2-oxo-4-morpholinecarboxylate and 700 ml of tetrahydrofuran, then cool the solution to  $-60^\circ\text{C}$  and add 700 ml of a 2M solution of lithium diisopropylamide in tetrahydrofuran and heptane, while maintaining the temperature of the reaction mixture below  $-40^\circ\text{C}$ . After reaction for 1 hour, add 225 g of allyl bromide while maintaining the temperature of the reaction mixture at  $-30^\circ\text{C}$ , and stir for 3 hours.

Subsequently, return the reaction to ambient temperature, hydrolyse with an aqueous ammonium chloride solution, extract with ether and wash the ethereal phase with water.



The tert-butyl (3S,5S)-3-allyl-5-methyl-2-oxo-4-morpholinecarboxylate isolated by concentrating the ethereal phase to dryness is used as it is in the following Step.

Step B : *tert-Butyl (3S,5S)-5-methyl-3-propyl-2-oxo-4-morpholinecarboxylate* :

Introduce into a hydrogenation vessel 200 g of the compound obtained in the above Step in solution in ethanol, followed by 5 g of 10 % Pd/C. Hydrogenate at normal pressure and ambient temperature until the theoretical amount of hydrogen has been absorbed.

Remove the catalyst by filtration, then isolate the tert-butyl (3S,5S)-5-methyl-3-propyl-2-oxo-4-morpholinecarboxylate by concentrating to dryness.

Step C : *Ethyl (2S)-2-{(tert-butoxycarbonyl)[(1S)-2-hydroxy-1-methylethyl]amino}-pentanoate*

Introduce into a reactor 200 g of the compound obtained in the above Step, 500 ml of acetonitrile, 500 ml of water and 500 ml of hexane, and then add 33 g of lithium hydroxide hydrate and stir for 3 hours at 0°C.

The reaction mixture is then concentrated to dryness and the lithium salt obtained is dissolved in 1.5 litres of dimethylformamide and subsequently treated with 122 g of iodoethane at ambient temperature.

After removal of the dimethylformamide by evaporation, the residue obtained by concentrating to dryness is taken up in ethanol and filtered over silica to give ethyl (2S)-2-{(tert-butoxycarbonyl)[(1S)-2-hydroxy-1-methylethyl]amino}pentanoate in a yield of 60 %.

Step D : *N-[(S)-Ethoxycarbonyl-1-butyl]-N-(tert-butoxycarbonyl)-(S)-alanine*


Introduce into a reactor 500 ml of dichloromethane, 500 ml of water and 500 ml of acetonitrile, and then add 141 g of sodium periodate and 1.35 g of hydrated ruthenium trichloride. Stir for 1 hour and add, rapidly, 200 g of the compound obtained in the above Step. At the end of the reaction, filter over Celite<sup>®</sup>, wash the organic phase and evaporate it to dryness to yield N-[(S)-ethoxycarbonyl-1-butyl]-N-(tert-butoxycarbonyl)-(S)-alanine.

Step E : *N-[(S)-Ethoxycarbonyl-1-butyl]-(S)-alanine hydrochloride* :

Introduce into a reactor 200 g of the compound obtained in the above Step and 1.5 litres of ethyl acetate, then bring the reaction mixture to 0°C and pass a stream of HCl gas through it for 30 minutes. After stirring overnight at ambient temperature, the precipitate formed is filtered off, rinsed and dried to give N-[(S)-ethoxycarbonyl-1-butyl]-(S)-alanine hydrochloride in quantitative yield.


# CLAIMS

## 1. Process for the synthesis of the compounds of formula (I)




wherein R represents a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group,

characterised in that a morpholinone of formula (III) :



wherein P represents a protecting group for the amino function,  
is reacted

- either with allyl bromide or allyl triflate, in the presence of a base, to yield a compound of formula (IV) having the (3S,5S) configuration :




wherein P is as defined hereinbefore,

which is hydrogenated in the presence of palladium-on-carbon,

- or with iodopropane,


to yield a compound of formula (V) :



wherein P is as defined hereinbefore,

- 5 which is subjected to the action of LiOH, then to the action of an esterification reagent,

to yield a compound of formula (VI) :



wherein R and P are as defined hereinbefore,

- 10 which is reacted with an oxidising agent to yield, after deprotection of the amino function, the compound of formula (I).


2. Synthesis process according to claim 1, allowing a compound of formula (I) wherein R represents an ethyl group to be obtained.
3. Synthesis process according to either claim 1 or claim 2, characterised in that P represents a tert-butoxycarbonyl group.
4. Synthesis process according to any one of claims 1 to 3, characterised in that the base used for the reaction between the compound of formula (III) and allyl bromide or allyl

triflate is lithium diisopropylamide, sodium bis(trimethylsilyl)amide or potassium tert-butanolate.

5. Synthesis process according to any one of claims 1 to 4, characterised in that the esterification reagent is iodoethane.


5 6. Synthesis process according to any one of claims 1 to 5, characterised in that the oxidising agent is  $\text{NaIO}_4$  in the presence of  $\text{RuCl}_3$ .

7. Compound of formula (V) :



wherein P represents a tert-butoxycarbonyl group.

10 8. Compound of formula (VI) :




wherein P represents a tert-butoxycarbonyl group and R represents an ethyl group.

9. Process for the synthesis of perindopril or pharmaceutically acceptable salts thereof starting from a compound of formula (I), characterised in that the said compound of formula (I) is obtained according to the process of claim 1.

**ABSTRACT**

**NEW PROCESS FOR THE SYNTHESIS OF  
N-[(S)-1-CARBOXYBUTYL]-(S)-ALANINE ESTERS  
AND APPLICATION IN THE SYNTHESIS OF PERINDOPRIL**

- 5 Process for the synthesis of compounds of formula (I) :



wherein R represents a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group.

Application in the synthesis of perindopril and its pharmaceutically acceptable salts.